Trevi Therapeutics prices $141M equity offering to fund Phase 3 chronic cough trials through 2029

Filed April 17, 2026 · Period ending April 16, 2026 · ~1 min read

Key Changes

• high

  Priced 11.6M share offering at $13.00/share with Morgan Stanley and Leerink Partners as underwriters, raising ~$141M net proceeds (~$162M if greenshoe fully exercised). Offering expected to close April 20, 2026.

  Item 1.01 verify on EDGAR →
• high

  Company held $171.8M in cash as of March 31, 2026. Combined with offering proceeds, management believes it can fund operations through 2029, including two Phase 3 IPF chronic cough trials potentially through FDA approval.

  Item 7.01 view on EDGAR →
• high

  First Phase 3 IPF trial will enroll ~300 patients with 52-week dosing, primary endpoint at 24 weeks, topline results expected H1 2028. Second trial will enroll ~130 patients with 12-week dosing, topline results expected H2 2027.

  Item 7.01 view on EDGAR →